Abstract 1757P
Background
Breast cancer is a crucially prevailing cancer among women. Early detection and diagnosis of breast cancer are very important for patient survival. This study was conducted to devise a cost-effective and robust community-based breast cancer screening programme for LMIC.
Methods
All enrolled participants will undergo breast thermogram (BT) using an AI-based Thermalytix test along with clinical breast examination (CBE) by trained health workers. Women found suspicious in either CBE/BT or both will undergo confirmatory tests using Sonomammography (US) and/or Mammography; biopsy, where warranted, will be done to confirm the diagnosis. All symptomatic and asymptomatic women aged above 35 years of age, willing to give written informed consent for study participation were included. Those who are pregnant or lactating, treated for any cancers of breast/thorax, active inflammatory disorders on the skin of the breast, breast implants that can hamper testing using a BT or CBE were excluded from this study. The primary study endpoint is to evaluate the effectiveness of combined modality testing for breast cancer detection in healthy women. The benefit of a combined modality of Thermogram and clinical breast examination (CBE) for cancer detection rate were evaluated.
Results
A total of 3030 (both symptomatic and asymptomatic women) were screened for breast cancers over a period of 6months (Oct 2022 to April 2023). Women residing within a 120square kilometre radius were screened. Patients who were detected with screen abnormality on a thermogram B- Score 4 and above were 561 (18.51%). Six hundred and forty-six subjects (21.3%) who had an abnormality on both thermogram and CBE were recalled for further investigations. Out of which 5 subjects were detected with biopsy-proven breast malignancy (3 were early-stage breast cancer and 2 had locally advanced breast cancer).
Conclusions
Dual modality screening tool improves cancer detection rates, and this demonstrates the efficacy of these tools for breast cancer screening. Thermalytix with its artificial intelligence-based scoring system can assist the health care worker in the detection of breast cancer at a community level.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. Ravind.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1706P - Time to full approval of novel anticancer medicines granted accelerated approval and implications for reform of the accelerated approval pathway
Presenter: Thomas Hwang
Session: Poster session 23
1707P - Cancer drug prices in the US: Efficacy, innovation, clinical trial evidence, and epidemiology
Presenter: Christoph Michaeli
Session: Poster session 23
1708P - The registration pathways in China for globally developed novel anticancer drugs
Presenter: Da-wei Wu
Session: Poster session 23
1709P - Influence of censoring on conclusions of FDA-approved cancer drugs using the modified time to treatment failure
Presenter: Jonathan Ofer
Session: Poster session 23
1710P - Protocol waivers and consequences on treatment safety and efficacy in the Drug Rediscovery Protocol (DRUP)
Presenter: Laurien Zeverijn
Session: Poster session 23
1711P - The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine
Presenter: Hans Gelderblom
Session: Poster session 23
1712P - Implementation of a molecular pre-screening program (MPP) in a network of public cancer centres for phase I clinical trial (Ph1-CT) candidates: The PREICO program
Presenter: Juan José Soto Castillo
Session: Poster session 23
1713P - Non-inferiority oncology clinical trials in major journals: Purposes, methods and results
Presenter: Rafael Barreto
Session: Poster session 23
1714P - Geographical disparities in access to cancer clinical trials in Korea
Presenter: Sokbom Kang
Session: Poster session 23
1715P - Analysis of the adequacy of control arms in oncology randomized clinical trials published between 2017 and 2021: A meta-research study
Presenter: Alessandro Rossi
Session: Poster session 23